New drug cocktail aims to tame rare liver disease
NCT ID NCT05239468
First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study tested whether adding bezafibrate to the standard drug obeticholic acid helps people with primary biliary cholangitis, a rare liver disease. 72 adults took part, and researchers measured changes in a key liver enzyme over 12 weeks. The goal is to see if the combination works better than either drug alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bezafibrate and obeticholic acid
- What this could lead to
- If it works, this combination could offer a new way to control primary biliary cholangitis and improve liver health.
- What could go wrong
- This is an early Phase 2a trial with only 72 people. It may not show clear benefit, and side effects like gallbladder problems are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
-
Beth Israel Deaconess Medical Center Harvard Liver Research Center
Boston, Massachusetts, 02215, United States
-
DIM Clinical Privada
Ramos Mejía, Buenos Aires, Argentina
-
Facey Medical Group
Mission Hills, California, 91345, United States
-
Gastro One
Cordova, Tennessee, 38018, United States
-
Gastrointestinal Associates of Northeast Tennessee
Johnson City, Tennessee, 37604, United States
-
Hospital Italiano La Plata
La Plata, Buenos Aires, Argentina
-
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
-
Hospital Provincial del Centenario
Rosario, Argentina
-
Hospital Universitario Austral
Pilar, Argentina
-
Houston Methodist Cancer Center
Houston, Texas, 77030-2717, United States
-
Loyola University Medical Center
Maywood, Illinois, 60459, United States
-
Methodist Clinical Research Institute (CRI)
Dallas, Texas, 75203, United States
-
NYU Langone Medical Center
New York, New York, 10016-6402, United States
-
Ochsner Medical Center
New Orleans, Louisiana, 70121, United States
-
Pacific Gastroenterology Associates
Vancouver, British Columbia, V6Z 2K5, Canada
-
Piedmont Atlanta Hospital
Atlanta, Georgia, 30309, United States
-
Schiff Center for Liver Diseases / University of Miami
Miami, Florida, 33136, United States
-
Southern California Gastrointestinal (GI) and Liver Centers (SCLC) - Coronado
Coronado, California, 92118, United States
-
Tampa General Medical Group
Tampa, Florida, 33606, United States
-
The Northern Alberta Clinical Trials and Research Centre
Edmonton, Alberta, T6G 287, Canada
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Montreal
Montreal, Quebec, Canada
-
Wake Endoscopy Center
Raleigh, North Carolina, 27607, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Can a smartwatch help manage a rare liver disease? stanford study investigates
- New study tracks blood sugar in liver disease patients on common drug
- Promising new treatment for rare liver disease shows potential in Late-Stage trial
- 800-Patient study aims to unlock secrets of autoimmune liver disease